About Kissei Pharmaceutical
Kissei Pharmaceutical is a company based in Matsumoto (Japan) founded in 1946. The company has 1,780 employees as of March 31, 2024. Kissei Pharmaceutical operates in a competitive market with competitors including Amyris, Avidity Biosciences, Arbor Biotechnologies, Univercells and Sutro Biopharma, among others.
- Headquarter Matsumoto, Japan
- Employees 1780 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Kissei Pharmaceutical Co., Ltd.
-
Annual Revenue
$591.1 M (USD)16.87as on Mar 31, 2025
-
Net Profit
$80.04 M (USD)7.17as on Mar 31, 2025
-
EBITDA
$70.73 M (USD)27.8as on Mar 31, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1780
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Kissei Pharmaceutical
Kissei Pharmaceutical is a publicly listed company on the TSE with ticker symbol 4547 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Kissei Pharmaceutical
Detailed funding history for Kissei Pharmaceutical
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kissei Pharmaceutical
Investment portfolio details for Kissei Pharmaceutical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kissei Pharmaceutical
Detailed financials for Kissei Pharmaceutical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kissei Pharmaceutical Comparisons
Peer comparison for Kissei Pharmaceutical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kissei Pharmaceutical
Kissei Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Amyris, Avidity Biosciences, Arbor Biotechnologies, Univercells and Sutro Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Genomic technologies and drug discovery platforms are provided.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
Detailed competitors of Kissei Pharmaceutical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kissei Pharmaceutical
Complete news archive for Kissei Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kissei Pharmaceutical
Kissei Pharmaceutical was founded in 1946.
Kissei Pharmaceutical is headquartered in Matsumoto, Japan. It is registered at Matsumoto, Nagano, Japan.
As of Mar 31, 2024, the latest employee count at Kissei Pharmaceutical is 1,780.
Annual revenue of Kissei Pharmaceutical is $591.1M as on Mar 31, 2025.
Kissei Pharmaceutical was founded in 1946 in Matsumoto, Japan, and operates within the pharmaceutical sector. Focus is placed on developing treatments for renal diseases and anemia associated with urology conditions. The lead product, JR-131, an injectable form of re-engineered erythropoietin, has completed phase III clinical trials for anemia management. Operations emphasize research and clinical advancement in these therapeutic areas.
Kissei Pharmaceutical's top competitors include Sutro Biopharma, Avidity Biosciences and Arbor Biotechnologies.
Yes, Kissei Pharmaceutical is publicly traded on TSE under the ticker symbol 4547.
The ticker symbol of Kissei Pharmaceutical is 4547 on TSE.